TB champions, associations and civil society have been playing a pivotal role in pushing back against patent monopolies and high prices that, for more than a decade, have kept newer and safer TB drugs out of the hands of people who ...

Activists present ‘Time for $5’ petition signed by over 206,000 people asking US corporations Cepheid and Danaher to drop test prices

MSF report shows many countries lag behind in aligning national paediatric TB policies with WHO guidelines

MSF responds to WHO recommendation of three new regimens of shorter, all-oral TB regimens, outlines the importance of affordable access to these regimens.

Indian Patent Office’s rejection of J&J’s patent application on lifesaving paediatric TB drug bedaquiline significant step for increasing affordable access.

MSF welcomes withdrawal of patents on TB drug bedaquiline in South Africa

MSF urges the EU/EEA to remove access barriers to TB medicines and update policies and practices in line with WHO treatment guidelines.

MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products

endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.